HST Global, Inc. Posts Second-Quarter Results

HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC) today announced its unaudited results for the second quarter ended June 30, 2008.

Net revenues for the second quarter of 2008 were $0. The net loss for the quarter was ($720,084), or ($0.16) per share. The weighted average number of common shares outstanding, on a fully diluted basis, for the three months ended June 30, 2008 was 4,497,569. There are currently 20,241,568 shares issued and outstanding.

Net revenues for the six month period ending June 30, 2008, were $0. The net loss for the six-month period was ($839,579), or ($0.19) per share. The weighted average number of common shares outstanding, on a fully diluted basis, for the nine-months ended June 30, 2008 was 4,497,569. There are currently 20,241,568 shares issued and outstanding.

Ron Howell, HST Global Inc.’s President and CEO, stated “The research funded by the Company is part of its strategic initiatives to generate future growth. These initiatives include capitalizing on the growth potential of HST Global, Inc. through further study of its current stage IV breast cancer drug candidate Salicinium, as well as, other items.”

More detailed information regarding the Company’s results of operations for the quarter ending June 30, 2008 can be found in the Company’s Form 10-QSB filing located on www.sec.gov.

About HST Global, Inc.

HST Global, Inc. is a development stage biotechnology company that acquires and develops innovative products for the treatment of cancer. We focus on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer, and then developing those drug candidates for commercial use.

HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2008 AND
FOR THE PERIOD FROM THE DATE OF INCEPTION (AUGUST 6, 2007) TO JUNE 30, 2008
		Three Months Ended June 30, 2008				Six Months Ended June 30, 2008				From Date of Inception (8/6/07) to June 30, 2008
REVENUES		$	-			$	-			$	-
COST OF SALES		$	-			$	-			$	-
GROSS PROFIT		$	-			$	-			$	-
OPERATING EXPENSES:
Salaries		$	30,690			$	38,767			$	68,767
Consulting			546,000				611,000				641,000
General and administrative expenses			143,394				189,812				192,549
TOTAL OPERATING EXPENSES		$	720,084			$	839,579			$	902,316
NET (LOSS)		$	(720,084	)		$	(839,579	)		$	(902,316	)
NET INCOME (LOSS) PER SHARE:
BASIC AND DILUTED - COMMON		$	(0.16	)		$	(0.19	)
WEIGHTED AVERAGE SHARES OUTSTANDING:
BASIC AND DILUTED - COMMON			4,497,569				4,497,569